
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Nano X Imaging Ltd (NNOX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/05/2025: NNOX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -43.98% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 282.66M USD | Price to earnings Ratio - | 1Y Target Price 11.75 |
Price to earnings Ratio - | 1Y Target Price 11.75 | ||
Volume (30-day avg) 3478666 | Beta 1.98 | 52 Weeks Range 4.61 - 11.39 | Updated Date 04/1/2025 |
52 Weeks Range 4.61 - 11.39 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.86 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.15 | Actual -0.17 |
Profitability
Profit Margin - | Operating Margin (TTM) -499.17% |
Management Effectiveness
Return on Assets (TTM) -16.55% | Return on Equity (TTM) -27.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 243415060 | Price to Sales(TTM) 25.05 |
Enterprise Value 243415060 | Price to Sales(TTM) 25.05 | ||
Enterprise Value to Revenue 22.79 | Enterprise Value to EBITDA -7.41 | Shares Outstanding 58521900 | Shares Floating 60350734 |
Shares Outstanding 58521900 | Shares Floating 60350734 | ||
Percent Insiders 9 | Percent Institutions 24.8 |
Analyst Ratings
Rating 5 | Target Price 15 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nano X Imaging Ltd

Company Overview
History and Background
Nano X Imaging Ltd. was founded in 2018 by Hitoshi Masuya. Its primary goal is to democratize medical imaging through the development of a novel digital X-ray source. It went public in 2020.
Core Business Areas
- Medical Imaging Solutions: Develops, manufactures, and commercializes a novel digital X-ray source technology designed to reduce the cost and increase the availability of medical imaging services.
Leadership and Structure
Erez Meltzer serves as the Chief Executive Officer. The company has a board of directors overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- Nanox.ARC: A multi-source digital X-ray device designed to provide 3D tomosynthesis imaging, pending regulatory approvals. Market share is currently negligible as the product is not yet widely commercially available. Competitors include traditional X-ray system manufacturers like GE Healthcare, Siemens Healthineers, and Philips.
- Nanox.CLOUD: A cloud-based infrastructure that will enable the expected future deployment and operation of the Nanox System and will provide a global infrastructure connecting medical imaging sources to radiologists and healthcare providers. Market share is also negligible because the first product using this platform is Nanox.ARC. Competitors include cloud-based medical imaging solutions offered by companies like IBM Watson Health and Amazon Web Services (AWS).
Market Dynamics
Industry Overview
The medical imaging market is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. However, accessibility and cost remain challenges.
Positioning
Nano X Imaging aims to disrupt the medical imaging market by offering a lower-cost, more accessible alternative to traditional X-ray systems. Its competitive advantage hinges on its novel digital X-ray source technology and pay-per-scan business model.
Total Addressable Market (TAM)
The global medical imaging market is expected to reach hundreds of billions of dollars. Nanox aims to capture a significant share by democratizing access to medical imaging, particularly in underserved areas.
Upturn SWOT Analysis
Strengths
- Novel digital X-ray source technology
- Potential for lower-cost imaging
- Cloud-based infrastructure
- Pay-per-scan business model
Weaknesses
- Limited commercialization to date
- Dependence on regulatory approvals
- Questionable historical test results
- High cash burn rate
Opportunities
- Expanding access to medical imaging in developing countries
- Partnerships with healthcare providers and insurers
- Development of new applications for digital X-ray technology
- Growth in telemedicine
Threats
- Competition from established medical imaging companies
- Technological obsolescence
- Regulatory hurdles
- Negative perceptions about the company from controversial media
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens (SIEGY)
- Philips (PHG)
Competitive Landscape
Nano X Imaging aims to compete with established players by offering a lower-cost, more accessible solution. However, it faces significant challenges in gaining market share and building trust with healthcare providers.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage and lack of substantial commercial product sales.
Future Projections: Future growth is highly dependent on obtaining regulatory approvals and successfully commercializing its Nanox.ARC system. Analyst estimates vary widely due to the uncertainty surrounding the company's prospects.
Recent Initiatives: Focus on securing regulatory approvals (FDA in the US), expanding manufacturing capabilities, and establishing partnerships with potential customers.
Summary
Nano-X Imaging is attempting to revolutionize the medical imaging field through the utilization of a brand new x-ray technology at a far lower price point; however, there is the significant risk of FDA approval and adoption from healthcare providers. The company has little to no revenue and is operating at a loss. With positive revenue the company will improve as its market cap is low right now. Nano-X needs to continue to work towards FDA approval and continue to develop partnerships.
Similar Companies
- GE
- PHG
- SIEG
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Market Research Reports, Company Website
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. The information provided is subject to change and should not be considered a recommendation to buy or sell Nano X Imaging stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nano X Imaging Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-21 | CEO & Acting Chairman of the Board Mr. Erez I. Meltzer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 164 | Website https://www.nanox.vision |
Full time employees 164 | Website https://www.nanox.vision |
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company was incorporated in 2018 and is headquartered in Petah Tikva, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.